The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction
File version
Author(s)
Schmidt, CW
Lopez, JA
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
39051 bytes
File type(s)
application/pdf
Location
Abstract
Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer.
Journal Title
Breast Cancer Research
Conference Title
Book Title
Edition
Volume
8
Issue
1
Thesis Type
Degree Program
School
Publisher link
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2006 Pinzon-Charry, et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Oncology and carcinogenesis